Top

Published in:

Open Access 01-04-2020 | Lymphoma | Original Article

miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma

Authors: Xinwei Li, Xueying Xu, Keng Chen, Haijian Wu, Yirong Wang, Shuxu Yang, Kun Wang

Published in: Pathology & Oncology Research | Issue 2/2020

Abstract

Primary central nervous system lymphoma (PCNSL) is an aggressive and rare subtype of non-Hodgkin lymphoma, arising exclusively in the CNS with a poor prognosis. Previous evidence has proved that MGMT was a promising target involving in TMZ resistance of PCNSL. Our study described a new miR-370-mediated mechanism of MGMT regulation in PCNSL. We first showed that miR-370 was downregulated in PCNSL tissues, while MGMT was inversely overexpressed. It was also observed that miR-370 suppressed the expression of MGMT. Additionally, upregulation of miR-370 significantly increased TMZ sensitivity dependent of MGMT, thus suppressed Raji cell proliferation and induced apoptosis in vitro. In conclusion, these results suggest that miR-370 is a potential target in PCNSL treatment.

Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24(8):1281–1288PubMed

Korfel A, Schlegel U (2013) Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 9(6):317–327PubMed

Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, Kaplan RS, O'Neill BP (2002) The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95(7):1504–1510PubMed

Ferreri AJ, Verona C, Politi LS, Chiara A, Perna L, Villa E, Reni M (2011) Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys 80(1):169–175PubMed

Moise L, Matta C, Hanna C, Pilorge S, Fermé C, Durrbach A, Ribrag V (2011) Methotrexate- and/or cytarabine-based chemotherapy may be effective and safe in solid-organ transplant recipients with primary central nervous system lymphomas. Leuk Lymphoma 52(3):521–524PubMed

Shi X, Zhang X, Yi C, Wang X, Chen Z, Zhang B (2013) The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients. Clin Nucl Med 38(2):98–102PubMed

Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP, Trevor J, Glaser MG, Lantos P, Ironside JW, Moss TH, Brada M, Whaley JB, Stenning SP (2000) A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89(6):1359–1370PubMed

Panageas KS, Elkin EB, DeAngelis LM, Ben-Porat L, Abrey LE (2005) Trends in survival from primary central nervous system lymphoma, 1975–1999: a population-based analysis. Cancer 104(11):2466–2472PubMed

Herrlinger U, Kuker W, Platten M (2002) First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 58(10):1573–1574PubMed

10.

Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell'Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJ (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40(11):1682–1688PubMed

11.

Reni M, Ferreri AJ, Landoni C, Villa E (2000) Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92(7):575–576PubMed

12.

Strik HM, Spreer A, Nagel H, Jacob S, Jung W, Kitze B, Bähr M (2004) Clinical response following adjuvant temozolomide in a patient with primary cerebral lymphoma. Anticancer Res 24(6):4121–4125PubMed

13.

Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96(6):864–867PubMedPubMedCentral

14.

Wang K, Xie D, Xie J, Wan Y, Ma L, Qi X, Yang S (2015) MiR-27a regulates Wnt/beta-catenin signaling through targeting SFRP1 in glioma. Neuroreport 26(12):695–702PubMed

15.

Wang K, Wang X, Zou J, Zhang A, Wan Y, Pu P, Song Z, Qian C, Chen Y, Yang S, Wang Y (2013) miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via nemo-like kinase. Neuro-Oncology 15(5):578–588PubMedPubMedCentral

16.

Yang S, Wang K, Qian C, Song Z, Pu P, Zhang A, Wang W, Niu H, Li X, Qi X, Zhu Y, Wang Y (2012) A predicted miR-27a-mediated network identifies a signature of glioma. Oncol Rep 28(4):1249–1256PubMed

17.

Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A, Kharenko O, Sitbon E, Lithwick Yanai G, Elyakim E, Cholakh H, Gibori H, Spector Y, Bentwich Z, Barshack I, Rosenfeld N (2009) MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 19(3):375–383PubMedPubMedCentral

18.

DeAngelis LM (2015) Neuro-oncology: primary CNS lymphoma treatment-the devil is in the details. Nat Rev Neurol 11(6):314–315PubMed

19.

Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K (2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neuro-Oncol 85(2):207–211

20.

Reni M, Mazza E, Foppoli M, Ferreri AJ (2007) Primary central nervous system lymphomas: salvage treatment after failure to high dose methotrexate. Cancer Lett 258(2):165–170PubMed

21.

Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U (2010) Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neuro-Oncol 97(3):389–392

22.

Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63(5):901–903PubMed

23.

Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K (2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neuro-Oncol 85(2):207–211

24.

Yungang W, Xiaoyu L, Pang T, Wenming L, Pan X (2014) miR-370 targeted FoxM1 functions as a tumor suppressor in laryngeal squamous cell carcinoma (LSCC). Biomed Pharmacother 68(2):149–154PubMed

25.

Chen XP, Chen YG, Lan JY, Shen ZJ (2014) MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer Lett 353(2):201–210PubMed

26.

Feng Y, Wang L, Zeng J, Shen L, Liang X, Yu H, Liu S, Liu Z, Sun Y, Li W, Chen C, Jia J (2013) FoxM1 is overexpressed in helicobacter pylori-induced gastric carcinogenesis and is negatively regulated by miR-370. Mol Cancer Res 11(8):834–844PubMed

27.

Zhang X, Zeng J, Zhou M, Li B, Zhang Y, Huang T, Wang L, Jia J, Chen C (2012) The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer 11:56PubMedPubMedCentral

28.

Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E (2011) Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro-Oncology 13(10):1090–1098PubMedPubMedCentral

29.

Zheng J, Xu J, Ma S, Sun X, Geng M, Wang L (2013) Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas. Int J Clin Exp Pathol 6(10):2048–2055PubMedPubMedCentral

30.

Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, Rosati S, Schuuring E, Kluin P, van den Berg A (2009) Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol 22(4):547–555PubMed

31.

Sun G, Hou YB, Jia HY, Bi XH, Yu L, Chen DJ (2016) MiR-370 promotes cell death of liver cancer cells by Akt/FoxO3a signalling pathway. Eur Rev Med Pharmacol Sci 20(10):2011–2019PubMed

32.

Cao X, Liu D, Yan X, Zhang Y, Yuan L, Zhang T, Fu M, Zhou Y, Wang J (2013) Stat3 inhibits WTX expression through up-regulation of microRNA-370 in Wilms tumor. FEBS Lett 587(6):639–644PubMed

33.

Gao Y, Chen X, Liu H (2016) Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression. Sci Rep 6:32972

Title: miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma
Authors: Xinwei Li
Xueying Xu
Keng Chen
Haijian Wu
Yirong Wang
Shuxu Yang
Kun Wang
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keyword: Lymphoma
Published in: Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00605-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma

Selective Inhibition of HIF1α Expression by ZnSO4 Has Antitumoral Effects in Human Melanoma

Bioinformatics Analysis Makes Revelation to Potential Properties on Regulation and Functions of Human Sox2

Expressions of Carbohydrate Response Element Binding Protein and Glucose Transporters in Liver Cancer and Clinical Significance

Upregulation of RUNX1 Suppresses Proliferation and Migration through Repressing VEGFA Expression in Hepatocellular Carcinoma

Relative and Absolute Expression Analysis of MicroRNAs Associated with Luminal A Breast Cancer– A Comparison

Keynote webinar | Spotlight on antibody–drug conjugates in cancer